NCT04748757View on ClinicalTrials.gov

Annexin A5 in Patients With Severe COVID-19 Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 20, 2021

Primary Completion Date

April 3, 2022

Study Completion Date

December 1, 2022

Conditions
Coronavirus InfectionSepsis
Interventions
DRUG

recombinant human annexin A5

recombinant human annexin A5, manufactured as SY-005

DRUG

Placebo

Normal saline 50 ml

Trial Locations (1)

N6A 5W9

London Health Sciences Centre, London

Sponsors
All Listed Sponsors
collaborator

Ontario Ministry of Colleges and Universities

UNKNOWN

collaborator

London Health Sciences Foundation

UNKNOWN

lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER